Compare MVST & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVST | RNA |
|---|---|---|
| Founded | 2006 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.1M | 222.5M |
| IPO Year | 2019 | 2025 |
| Metric | MVST | RNA |
|---|---|---|
| Price | $0.67 | $8.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 5.4M | 428.8K |
| Earning Date | 11-09-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $427,516,000.00 | N/A |
| Revenue This Year | N/A | $84.55 |
| Revenue Next Year | $29.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.56 | N/A |
| 52 Week Low | $0.56 | $7.96 |
| 52 Week High | $7.12 | $73.06 |
| Indicator | MVST | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 28.57 |
| Support Level | $0.56 | N/A |
| Resistance Level | $0.75 | $14.05 |
| Average True Range (ATR) | 0.04 | 0.46 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 49.27 | 12.41 |
Microvast Holdings Inc develops lithium-ion battery technologies focused on high-performance solutions for commercial and industrial electrification. The Company designs, develops, and manufactures battery components and systems for electric commercial vehicles and energy storage systems (ESS), with applications across buses, trucks, port equipment, and mining machinery. It emphasizes innovation in battery design without relying on legacy technologies and supports platforms such as the IVECO eDaily and various bus models. The Company also provides services, repairs, and warranty and extended warranty support. It operates as a single reportable segment, covering design, development, manufacturing, sales, and leasing of battery systems, and generates the majority of its revenue from Europe.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.